<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Pantoprazole - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Pantoprazole</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">GI</div>
      <h1>Pantoprazole</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Pantoprazole 40mg Tablets</li>
          <li>Pantoprazole 40mg Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>GERD / reflux symptoms or erosive esophagitis (common use)</strong></p>
        <ul>
          <li>40 mg PO once daily (typical course 4–8 weeks; reassess)</li>
        </ul>
        <p><strong>Suspected upper GI bleeding / significant ulcer bleed (protocol-dependent; higher-acuity use)</strong></p>
        <ul>
          <li>IV dosing varies by protocol; common approaches include:</li>
          <li>40–80 mg IV, then 8 mg/hour IV infusion (where capability/protocol exists)</li>
        </ul>
        <p><strong>Stress ulcer prophylaxis / high-risk gastritis (context-dependent)</strong></p>
        <ul>
          <li>40 mg PO or IV once daily (use local protocol)</li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>GERD, erosive esophagitis; peptic ulcer disease (provider-directed)</li>
          <li>Treatment/prevention of GI bleeding related to acid-mediated injury (protocol-dependent)</li>
          <li>When an IV PPI is required because PO is not feasible or patient is high acuity</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <p><strong>Contraindications</strong></p>
        <ul>
          <li>Hypersensitivity to pantoprazole/PPIs</li>
          <li>Concomitant use with rilpivirine (avoid)</li>
        </ul>
        <p><strong>Cautions (especially prolonged or high-dose use)</strong></p>
        <ul>
          <li>C. difficile–associated diarrhea risk; pneumonia risk in some settings</li>
          <li>Hypomagnesemia (especially with prolonged use), B12 deficiency (long-term), fracture risk (long-term)</li>
          <li>Possible interaction considerations with clopidogrel (follow local guidance)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Headache, diarrhea, abdominal pain, nausea</li>
          <li>IV: injection-site irritation/phlebitis (can occur)</li>
          <li>Rare but important: severe diarrhea (consider C. difficile), allergic reaction</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <p><strong>PO tablets</strong></p>
        <ul>
          <li>Swallow whole; do not crush/chew</li>
        </ul>
        <p><strong>IV injection/infusion (40 mg vial)</strong></p>
        <ul>
          <li>Reconstitute each 40 mg vial with 10 mL of 0.9% sodium chloride to yield ~4 mg/mL</li>
          <li>Administration options (protocol-dependent):</li>
          <li>IV injection of reconstituted solution</li>
          <li>IV infusion: further dilute and administer by infusion over ~15 minutes (see monograph for exact dilution examples)</li>
          <li>Use a dedicated line or flush before/after; do not run simultaneously with other IV solutions in the same line</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Symptom response (pain, reflux, hematemesis/melena if GI bleed context)</li>
          <li>For GI bleed contexts: hemodynamics, Hgb trends if available, ongoing bleeding signs</li>
          <li>With prolonged use: consider magnesium/B12 risk if clinically relevant</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>In suspected GI bleed, document timing/dose and reassess frequently; early escalation/evac planning if unstable or recurrent bleeding</li>
          <li>IV prep needs reliable IV access, compatible diluent, and clear labeling to avoid mix-ups</li>
          <li>If clopidogrel/ASA are being used, consider GI protection strategy per protocol and bleeding risk</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (tablets) (PDF): https://pdf.hres.ca/dpd_pm/00061763.PDF</li>
          <li>Health Canada product monograph (pantoprazole for injection) (PDF): https://pdf.hres.ca/dpd_pm/00054193.PDF</li>
          <li>BCEHS drug monograph (operational dosing reference): https://handbook.bcehs.ca/drug-monographs/pantoprazole/</li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
